Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Christin Lund-Andersen, Sigve Nakken, Ståle Nygård...
https://pubmed.ncbi.nlm.nih.gov/30862609/Actively Recruiting
Led by Oslo University Hospital · Updated on 2021-07-28
300
Participants Needed
1
Research Sites
260 weeks
Total Duration
Researchers are studying peritoneal surface malignancies PSM, a group of cancers affecting the lining of the abdomen, to improve treatment selection and outcomes. The study aims to find biomarkers that predict disease recurrence and prognosis and to explore new treatment strategies through animal models. This research is based on extensive experience, a large biobank, and novel models developed at a leading hospital. Participants are patients diagnosed with PSM who undergo cytoreductive surgery CRS combined with hyperthermic intraperitoneal chemotherapy HIPEC. CRS involves removing all visible tumors, while HIPEC delivers heated chemotherapy directly into the abdomen to target remaining cancer cells. This observational study collects and analyzes tissue and blood samples during treatment to better understand the disease and refine patient selection. During the study, participants will have their metastatic tissue and blood specimens collected for analysis. Researchers will monitor overall survival and disease-free survival over five years to assess outcomes. The study does not involve additional experimental treatments but focuses on gathering valuable data to guide future therapies. Participants progress will be tracked through routine clinical care and follow-up visits up to five years after treatment.
CONDITIONS
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
K
Kjersti Flatmark, MD PhD
A
Annette Torgunrud Kristensen, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Oslo University Hospital
Lead Sponsor
The Research Council of Norway
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Hospital stay duration as determined by clinical care
Participants undergo cytoreductive surgery (CRS) to remove visible tumors followed by heated chemotherapy (HIPEC) in the abdominal cavity to eliminate residual cancer disease. This phase involves complex treatment and significant recovery.
Duration - Up to 5 years
Participants are monitored after surgery and chemotherapy to track overall survival and disease-free survival over 5 years.
Regular visits over 5 years for monitoring
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Christin Lund-Andersen, Sigve Nakken, Ståle Nygård...
https://pubmed.ncbi.nlm.nih.gov/30862609/Oslo University Hospital
Lead Sponsor
The Research Council of Norway
Collaborating Sponsor